No Data
No Data
Harris Vs. Trump: 2024 Election Poll Shows Good, Bad News For Each Candidate
Teva Pharmaceutical Industries Limited's (NYSE:TEVA) Revenues Are Not Doing Enough For Some Investors
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Trump Vs. Harris: 2024 Election Betting Odds Show Vice President Maintains Lead As Race Nears One-Month Mark
Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $23
Teva Pharmaceutical's Movement Disorder Drug Shows Sustained Improvement in Extension Study
No Data
No Data